T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Apple
AAPL
|
+$4.53B |
| 2 |
Broadcom
AVGO
|
+$1.7B |
| 3 |
GE Vernova
GEV
|
+$1.29B |
| 4 |
International Paper
IP
|
+$1.11B |
| 5 |
Tesla
TSLA
|
+$956M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$2.44B |
| 2 |
NVIDIA
NVDA
|
+$2.09B |
| 3 |
Constellation Energy
CEG
|
+$1.9B |
| 4 |
Qualcomm
QCOM
|
+$1.84B |
| 5 |
Amazon
AMZN
|
+$1.56B |
Sector Composition
| 1 | Technology | 34% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.1% |
| 5 | Communication Services | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Cameco
CCJ
$33.7B
| $250M | 0.03% |
5,075,764
-1,438,736
| -22% | -$70.8M |
|
377
Moody's
MCO
$91B
| $249M | 0.03% |
590,440
+178,109
| +43% | +$75M |
|
378
Neurocrine Biosciences
NBIX
$14.3B
| $248M | 0.03% |
1,798,848
-21,948
| -1% | -$3.02M |
|
379
SS&C Technologies
SSNC
$21.7B
| $247M | 0.03% |
3,934,609
+74,353
| +2% | +$4.66M |
|
380
Domino's
DPZ
$15.8B
| $244M | 0.03% |
473,239
+28,459
| +6% | +$14.7M |
|
381
Workday
WDAY
$61.9B
| $244M | 0.03% |
1,092,952
-218,290
| -17% | -$48.8M |
|
382
BP
BP
$87.8B
| $243M | 0.03% |
6,740,818
+225,279
| +3% | +$8.13M |
|
383
Ascendis Pharma
ASND
$12.4B
| $243M | 0.03% |
1,784,148
+2,222
| +0.1% | +$303K |
|
384
Snowflake
SNOW
$76.7B
| $242M | 0.03% |
1,794,685
-97,996
| -5% | -$13.2M |
|
385
lululemon athletica
LULU
$19.6B
| $242M | 0.03% |
809,309
-203,994
| -20% | -$60.9M |
|
386
Madrigal Pharmaceuticals
MDGL
$10.1B
| $241M | 0.03% |
858,765
+55,552
| +7% | +$15.6M |
|
387
Celestica
CLS
$28.1B
| $240M | 0.03% |
4,187,469
-4,516,273
| -52% | -$259M |
|
388
Noble Corp
NE
$4.75B
| $240M | 0.03% |
5,371,955
-547,791
| -9% | -$24.5M |
|
389
VF Corp
VFC
$6.08B
| $240M | 0.03% |
17,748,881
+17,306,675
| +3,914% | +$234M |
|
390
Vaxcyte
PCVX
$4.21B
| $240M | 0.03% |
3,173,167
-3,014
| -0.1% | -$228K |
|
391
Verisk Analytics
VRSK
$38.1B
| $236M | 0.03% |
876,126
+419,452
| +92% | +$113M |
|
392
Kanzhun
BZ
$11.1B
| $233M | 0.03% |
12,381,493
-432,886
| -3% | -$8.14M |
|
393
Ares Management
ARES
$38.7B
| $231M | 0.03% |
1,734,896
-2,226,947
| -56% | -$297M |
|
394
ICICI Bank
IBN
$114B
| $229M | 0.03% |
7,945,724
-675,437
| -8% | -$19.5M |
|
395
CAVA Group
CAVA
$7.58B
| $226M | 0.03% |
2,439,389
-1,031,560
| -30% | -$95.7M |
|
396
Teck Resources
TECK
$17.2B
| $224M | 0.03% |
4,667,836
+166,758
| +4% | +$7.99M |
|
397
Louisiana-Pacific
LPX
$6.91B
| $223M | 0.03% |
2,710,779
+970,530
| +56% | +$79.9M |
|
398
OneMain Financial
OMF
$7.27B
| $223M | 0.03% |
4,593,161
+35,084
| +0.8% | +$1.7M |
|
399
Royal Caribbean
RCL
$95.4B
| $222M | 0.03% |
1,394,129
-183,623
| -12% | -$29.3M |
|
400
Huntington Ingalls Industries
HII
$10.6B
| $222M | 0.03% |
901,038
-164,074
| -15% | -$40.4M |
|